Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years

Ali Bazarbachi(American University of Beirut Medical Center), Mohamad Mohty(Inserm), Alexandros Spyridonidis(General University Hospital of Patras), Dietrich W. Beelen(Essen University Hospital), Didier Blaise(Institut Paoli-Calmettes), Fabio Ciceri(San Antonio College), Victoria Potter, Jaime Sanz(Memorial Sloan Kettering Cancer Center), Myriam Labopin(Sorbonne Université), Riitta Niittyvuopio, Christoph Schmid(University Hospital Augsburg), Arnon Nagler(Tel Aviv University), Igor Wolfgang Blau(Franklin University), Iman Abou Dalle(American University of Beirut Medical Center), Gesine Bug(Goethe University Frankfurt), Gèrard Socié(Hôpital Saint-Louis), Bipin N. Savani(Vanderbilt University Medical Center), Jordi Esteve(Hospital Clínic de Barcelona)
Clinical Cancer Research
September 28, 2020
10.1158/1078-0432.ccr-20-3134
Cited by 81

Related Papers

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.9k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k